Elegen is a biotechnology company specializing in synthetic DNA production, developing the ENFINIA™ DNA platform to deliver long, high-complexity, NGS-verified synthetic DNA rapidly without cloning or bacterial processes[1][2][3]. It serves researchers and scientists in agriculture, chemicals, healthcare, and pharma by solving the bottleneck of slow, inefficient traditional DNA synthesis, which can take weeks or months, enabling faster workflows for genetic medicine and synthetic biology with delivery in 6-8 business days and pricing as low as $0.07 per base pair[1][2][3][4]. Founded in 2017 and based in the San Francisco Bay Area, Elegen has shown growth through innovations like its GEN II production platform launched in early access by October 2025, recognized as a Top Biotechnology Company of 2024[1][3].
Elegen was founded in 2017 by Matthew Hill, PhD, who serves as CEO, driven by a vision to eliminate the DNA synthesis bottleneck in synthetic biology applications[1][3]. Hill brings decades of experience from Fluidigm, where he advanced core technologies in molecular biology, microfluidics, and chemistry as VP R&D, Chief Scientific Officer, and later EVP R&D and Marketing, helping the company go public with over $100M in annual product revenue[1]. The idea emerged from his expertise in scalable molecular approaches, leading to Elegen's proprietary cell-free, microfluidics-based platform as a faster alternative to traditional methods reliant on bacteria and plasmids[1][4]. Early traction built on this innovation, culminating in awards like Top Healthcare Technology Company of 2024 and recent GEN II advancements[1][3].
Elegen stands out in gene synthesis through these key advantages:
Elegen rides the synthetic biology wave, addressing the "DNA bottleneck" amid booming demand for rapid genetic engineering in a growing bioeconomy[2][3]. Timing aligns with advances in genetic medicine, mRNA therapies, and personalized treatments, where speed enables broader sequence exploration and simpler scale-up[1][2][3]. Market forces like rising needs in healthcare/pharma for endotoxin-free, high-complexity DNA favor its cell-free tech over traditional plasmid methods, which introduce variability and delays[1][4][5]. By catalyzing faster discoveries, Elegen influences the ecosystem, empowering builders to innovate in synbio without capital-intensive workflows and positioning itself as a leader in next-gen manufacturing[2][3].
Elegen's trajectory points to expanded dominance in synbio DNA production, with GEN II's early access signaling scaled manufacturing and new products like IVT-ready linear DNA[3]. Trends like AI-optimized biotech, mRNA expansion, and ethical synbio growth will propel it, potentially capturing more market share as bioeconomy demands accelerate[2][3][4]. Its influence may evolve into a foundational supplier, enabling breakthroughs in life-saving therapies while maintaining cost/speed edges—solidifying its role as the catalyst for a faster, more efficient biotech revolution[2].
Elegen has raised $35.0M in total across 1 funding round.
Elegen's investors include Builders VC, Highbury Group, KdT Ventures, Sofinnova Investments, VZVC, Wilbur-Ellis [Cavallo].
Elegen has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Series B in May 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2024 | $35.0M Series B | Builders VC, Highbury Group, KdT Ventures, Sofinnova Investments, VZVC, Wilbur-Ellis [Cavallo] |
